<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="5716">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 13, 2016</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01103271</url>
  </required_header>
  <id_info>
    <org_study_id>2009p002469</org_study_id>
    <secondary_id>K24AT004095</secondary_id>
    <nct_id>NCT01103271</nct_id>
  </id_info>
  <brief_title>Pilot Study of Open-label Placebo to Treat Major Depressive Disorder</brief_title>
  <official_title>Harnessing the Placebo Effect in Major Depressive Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Harvard University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Center for Complementary and Integrative Health (NCCIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Placebo pills (pills with no active ingredients) have been shown in research studies to
      somehow produce self-healing processes. The purpose of this study is to determine whether
      people will be willing to enter an open-label non-deceptive placebo treatment for Major
      Depressive Disorder (MDD) and whether open-label placebo can be effective for treating MDD
      in the context of a supportive physician-patient relationship.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>May 2010</start_date>
  <completion_date type="Actual">May 2011</completion_date>
  <primary_completion_date type="Actual">May 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Single Blind (Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Feasibility</measure>
    <time_frame>One year</time_frame>
    <safety_issue>No</safety_issue>
    <description>The primary outcome measure is feasibility, which was operationalized as the number of in-person screens for this study.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pre-Post Efficacy</measure>
    <time_frame>Screen and 4 weeks (immediate treatment); Baseline and 4 weeks (waitlist treatment)</time_frame>
    <safety_issue>No</safety_issue>
    <description>The magnitude of the pre-post effect across 4 weeks of treatment, as measured by the Hamilton Rating Scale for Depression-17 (HAMD-17). The HAMD-17 measures depression severity, and has a minimum value of 0 and a maximum value of 52 units on a scale, where higher scores indicate more severe depression.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Major Depressive Disorder</condition>
  <arm_group>
    <arm_group_label>Open-label Placebo Immediate Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Open-label Placebo Waitlist Treatment</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Open-label Placebo</intervention_name>
    <description>Participants take open-label placebo pills - two twice daily for four weeks.</description>
    <arm_group_label>Open-label Placebo Immediate Treatment</arm_group_label>
    <arm_group_label>Open-label Placebo Waitlist Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Men or women aged 18-60 years old.

          -  Current Major Depressive Disorder (MDD)

        Exclusion Criteria:

          -  Pregnant women or women of child bearing potential not using a medically accepted
             means of contraception.

          -  Patients who are a serious suicide or homicide risk.

          -  Unstable medical illness including cardiovascular, hepatic, renal, respiratory,
             endocrine, neurological, or hematological disease.

          -  The following Diagnostic and Statistical Manual of Mental Disorders-IV diagnoses: 1)
             organic mental disorders; 2) substance use disorders, including alcohol, active
             within the last year; 3) schizophrenia; 4) delusional disorder; 5) psychotic
             disorders not elsewhere classified; 6) bipolar disorder; 7) acute bereavement; 9)
             severe borderline or antisocial personality disorder; 10) current primary diagnoses
             of panic disorder, social phobia, generalized anxiety disorder (GAD), or obsessive
             compulsive disorder (OCD) (disorders that present as chief complaint and/or have
             their onset preceding the onset of major depressive disorder).

          -  Uncontrolled seizure disorder.

          -  Patients with mood congruent or mood incongruent psychotic features.

          -  Current use of other psychotropic drugs. Exception: Patients who have been on a
             stable dose for 30 days of classes of medications such as non-benzodiazepine
             sedatives, anxiolytic benzodiazepines, non-narcotic analgesics may be included.
             Flexibility will be allowed based on physician discretion.

          -  Clinical or laboratory evidence of hypothyroidism.

          -  Patients who have taken an investigational psychotropic drug within the last year.

          -  Patients who have not responded to two or more antidepressant trials of adequate
             doses (e.g., fluoxetine 40 mg/day or higher) and duration (e.g.,for six weeks or
             more) over the past five years.

          -  Any concomitant form of psychotherapy (depression focused)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maurizio Fava, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2013</verification_date>
  <lastchanged_date>January 8, 2013</lastchanged_date>
  <firstreceived_date>April 9, 2010</firstreceived_date>
  <firstreceived_results_date>May 2, 2012</firstreceived_results_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Maurizio Fava, MD</investigator_full_name>
    <investigator_title>Director, Depression Clinical and Research Program</investigator_title>
  </responsible_party>
  <keyword>depression</keyword>
  <keyword>placebo effect</keyword>
  <keyword>complementary therapies</keyword>
  <keyword>alternative therapies</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Depression</mesh_term>
    <mesh_term>Depressive Disorder</mesh_term>
    <mesh_term>Depressive Disorder, Major</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>A total of 33 participants were screened for this study.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Immediate Treatment</title>
          <description>Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.</description>
        </group>
        <group group_id="P2">
          <title>Waitlist Treatment</title>
          <description>Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immediate Treatment</title>
          <description>Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.</description>
        </group>
        <group group_id="B2">
          <title>Waitlist Treatment</title>
          <description>Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <measure_list>
        <measure>
          <title>Number of Participants</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>&lt;=18 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Between 18 and 65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>&gt;=65 years</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="0"/>
                <measurement group_id="B2" value="0"/>
                <measurement group_id="B3" value="0"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <category_list>
            <category>
              <measurement_list>
                <measurement group_id="B1" value="37.2" spread="12.0"/>
                <measurement group_id="B2" value="40.8" spread="13.7"/>
                <measurement group_id="B3" value="38.8" spread="12.6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>Female</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="8"/>
                <measurement group_id="B2" value="6"/>
                <measurement group_id="B3" value="14"/>
              </measurement_list>
            </category>
            <category>
              <sub_title>Male</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="3"/>
                <measurement group_id="B2" value="3"/>
                <measurement group_id="B3" value="6"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <category_list>
            <category>
              <sub_title>United States</sub_title>
              <measurement_list>
                <measurement group_id="B1" value="11"/>
                <measurement group_id="B2" value="9"/>
                <measurement group_id="B3" value="20"/>
              </measurement_list>
            </category>
          </category_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Feasibility</title>
        <description>The primary outcome measure is feasibility, which was operationalized as the number of in-person screens for this study.</description>
        <time_frame>One year</time_frame>
        <safety_issue>No</safety_issue>
        <population>The number of participants analyzed is the number of participants screened.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo Effect Study</title>
            <description>These were all participants who were screened for the study but not yet enrolled.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Feasibility</title>
            <description>The primary outcome measure is feasibility, which was operationalized as the number of in-person screens for this study.</description>
            <units>screens</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="33" spread="0"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pre-Post Efficacy</title>
        <description>The magnitude of the pre-post effect across 4 weeks of treatment, as measured by the Hamilton Rating Scale for Depression-17 (HAMD-17). The HAMD-17 measures depression severity, and has a minimum value of 0 and a maximum value of 52 units on a scale, where higher scores indicate more severe depression.</description>
        <time_frame>Screen and 4 weeks (immediate treatment); Baseline and 4 weeks (waitlist treatment)</time_frame>
        <safety_issue>No</safety_issue>
        <group_list>
          <group group_id="O1">
            <title>Open Label-Placebo: Immediate Treatment</title>
            <description>Participants assigned to immediate treatment will begin taking placebo pills for four weeks immediately after enrolling in the study.</description>
          </group>
          <group group_id="O2">
            <title>Placebo Comparator: Waitlist Treatment</title>
            <description>Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.</description>
          </group>
        </group_list>
        <measure_list>
          <measure>
            <title>Number of Participants</title>
            <units>participants</units>
            <param>Number</param>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="11"/>
                  <measurement group_id="O2" value="9"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
          <measure>
            <title>Pre-Post Efficacy</title>
            <description>The magnitude of the pre-post effect across 4 weeks of treatment, as measured by the Hamilton Rating Scale for Depression-17 (HAMD-17). The HAMD-17 measures depression severity, and has a minimum value of 0 and a maximum value of 52 units on a scale, where higher scores indicate more severe depression.</description>
            <units>units on a scale</units>
            <param>Mean</param>
            <dispersion>Standard Deviation</dispersion>
            <category_list>
              <category>
                <measurement_list>
                  <measurement group_id="O1" value="14.75" spread="6.61"/>
                  <measurement group_id="O2" value="3.25" spread="6.01"/>
                </measurement_list>
              </category>
            </category_list>
          </measure>
        </measure_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Immediate Treatment</title>
          <description>Participants will begin taking placebo pills for four weeks immediately after enrolling in the study.</description>
        </group>
        <group group_id="E2">
          <title>Waitlist Treatment</title>
          <description>Participants will wait two weeks after enrolling in the study to begin taking placebo pills for four weeks.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="11"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Maurizio Fava</name_or_title>
      <organization>Massachusetts General Hospital</organization>
      <phone>617-724-0838</phone>
      <email>mfava@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>
